The Oncology Institute Announces Resignation of Board Member Gabe Ling

Rhea-AI Summary

The Oncology Institute (NASDAQ: TOI) announced that Gabe Ling resigned from the Board of Directors, effective December 1, 2025. The company said a formal search has begun to add independent directors with healthcare, clinical, and value-based care expertise.

The board emphasized thanks for Ling’s service during the company’s early public-market years and stated a continuing focus on strengthening governance and recruiting strategic, experienced members to support long-term growth.

Positive

• Board member resignation effective December 1, 2025
• Formal search initiated for independent directors with clinical expertise

Negative

• No timeline provided for replacement of the vacant board seat

News Market Reaction – TOI

-6.37%

-6.37% Session close to close

In the Dec 1 session, TOI declined 6.37%, reflecting a notable negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock moved -6.4% in the session following this news. A negative reaction despite a relatively r...

Analysis

The stock moved -6.4% in the session following this news. A negative reaction despite a relatively routine board resignation would fit TOI’s recent pattern, where positive earnings and AI efficiency news coincided with declines of about 10%. Earlier board changes in August 2025 also saw a -10.49% move. With shares already trading below the 52-week high but above long-term averages, governance headlines have previously acted as pressure points, and disappointment around leadership stability could have amplified selling.

Key Figures

Resignation effective date: December 1, 2025

1 metrics

Resignation effective date December 1, 2025 Effective date of Gabe Ling’s board resignation

Historical Context

5 past events · Latest: Dec 01 (Neutral)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Dec 01	Board resignation	Neutral	-6.4%	Director Gabe Ling resigned; search for new independent directors began.
Nov 13	Earnings results	Positive	-10.2%	Q3 2025 revenue growth and raised 2025 guidance announced.
Nov 13	AI partnership	Positive	-10.2%	AI-based prior authorization automation with sizable time and cost savings.
Oct 22	Earnings call date	Neutral	+3.0%	Announced Q3 2025 earnings release timing and conference call details.
Oct 01	Conference participation	Neutral	-0.3%	Planned presentation at Noble Capital Markets virtual equity conference.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent positive fundamental and operational news for TOI often coincided with negative price reactions, including past management and board-related announcements.

Recent Company History

Over the last few months, TOI reported strong Q3 2025 growth, with revenue and gross profit increasing and full-year guidance raised, yet the stock fell 10.2%. A separate AI automation collaboration projected up to $2 million in 2026 savings but saw a similar decline. Conference participation and an earnings call announcement produced modest price moves. Earlier board changes in August 2025 triggered a -10.49% reaction. Today’s board resignation continues this period of active governance evolution for TOI.

Key Terms

value-based oncology, value-based care

2 terms

value-based oncology medical

"one of the largest value-based oncology groups in the United States"

Value-based oncology is an approach to cancer care that prioritizes treatments and care pathways that deliver the best patient outcomes relative to their cost, judging success by improvements in survival, quality of life, and fewer complications rather than by how many tests or procedures are done. For investors it matters because insurers and hospitals increasingly favor and pay for therapies, diagnostics, and care models that prove real benefit per dollar—like choosing a high‑mileage car over a gas guzzler—which affects which products gain market access, reimbursement rates, and long-term revenue.

value-based care medical

"complementary healthcare, clinical, and value-based care expertise"

A health-care delivery approach that rewards providers for keeping patients healthy and improving outcomes instead of charging for each test or visit. For investors, it matters because it shifts where profits and losses come from—favoring providers and technologies that lower long-term costs, prevent complications, and demonstrate measurable results; think of it like paying a contractor only when the house stays sound, which changes who wins and loses financially.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

CERRITOS, Calif., Dec. 01, 2025 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (“TOI”) (NASDAQ: TOI), one of the largest value-based oncology groups in the United States, today announced that Gabe Ling has resigned from the Board of Directors, effective December 1, 2025. A formal search process has been initiated to add new independent directors with complementary healthcare, clinical, and value-based care expertise.

“On behalf of the Board of Directors, I want to thank Gabe for his service during an important chapter in The Oncology Institute’s development,” said Anne McGeorge, Chairman of the Board. “We appreciate the contributions he made throughout his time on the Board and the valuable guidance he provided as the Company navigated its first few years in the public markets. As we continue to strengthen our governance structure, we remain focused on enhancing the Board’s capabilities by bringing on strategic and experienced members who will support The Oncology Institute’s mission and long-term growth goals.”

About The Oncology Institute
Founded in 2007, The Oncology Institute (NASDAQ: TOI) is advancing oncology by delivering highly specialized, value-based cancer care in the community setting. TOI offers cutting-edge, evidence-based cancer care to a population of approximately 1.9 million patients, including clinical trials, transfusions, and other care delivery models traditionally associated with the most advanced care delivery organizations. With over 180 employed and affiliate clinicians and over 100 clinics and affiliate locations of care across five states and growing, TOI is changing oncology for the better. For more information, visit www.theoncologyinstitute.com

Contacts

Media

The Oncology Institute, Inc.
marketing@theoncologyinstitute.com

Investors

ICR Healthcare
TOI@icrhealthcare.com

FAQ

Who resigned from The Oncology Institute board effective December 1, 2025 (TOI)?

Gabe Ling resigned from the Board of Directors, effective December 1, 2025.

What steps is The Oncology Institute (TOI) taking after Gabe Ling's resignation?

The company has initiated a formal search to add independent directors with healthcare, clinical, and value-based care expertise.

How will Gabe Ling's resignation affect The Oncology Institute's governance (TOI)?

The board said it is focused on strengthening governance by recruiting strategic, experienced directors to support long-term growth.

Does The Oncology Institute (TOI) provide a timeline for appointing new directors?

No timeline for appointments was provided in the announcement.

Who commented on Gabe Ling’s resignation from The Oncology Institute (TOI)?

Anne McGeorge, Chairman of the Board, thanked Gabe Ling for his service and guidance during the company’s early public years.